131 related articles for article (PubMed ID: 36000934)
1. Pregnancy in Women With HIV in a Tuberculosis Preventive Therapy Trial.
Singh P; Moulton LH; Barnes GL; Gupta A; Msandiwa R; Chaisson RE; Martinson NA
J Acquir Immune Defic Syndr; 2022 Dec; 91(4):397-402. PubMed ID: 36000934
[TBL] [Abstract][Full Text] [Related]
2. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Vernon A; Burman W; Benator D; Khan A; Bozeman L
Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
[TBL] [Abstract][Full Text] [Related]
3. Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis.
Yanes-Lane M; Ortiz-Brizuela E; Campbell JR; Benedetti A; Churchyard G; Oxlade O; Menzies D
PLoS Med; 2021 Sep; 18(9):e1003738. PubMed ID: 34520459
[TBL] [Abstract][Full Text] [Related]
4. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma SK; Sharma A; Kadhiravan T; Tharyan P
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
[TBL] [Abstract][Full Text] [Related]
5. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Mathad JS; Savic R; Britto P; Jayachandran P; Wiesner L; Montepiedra G; Norman J; Zhang N; Townley E; Chakhtoura N; Bradford S; Patil S; Popson S; Chipato T; Rouzier V; Langat D; Chalermchockcharoentkit A; Kamthunzi P; Gupta A; Dooley KE
Clin Infect Dis; 2022 May; 74(9):1604-1613. PubMed ID: 34323955
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
[TBL] [Abstract][Full Text] [Related]
8. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.
Churchyard G; Cárdenas V; Chihota V; Mngadi K; Sebe M; Brumskine W; Martinson N; Yimer G; Wang SH; Garcia-Basteiro AL; Nguenha D; Masilela L; Waggie Z; van den Hof S; Charalambous S; Cobelens F; Chaisson RE; Grant AD; Fielding KL;
Ann Intern Med; 2021 Oct; 174(10):1367-1376. PubMed ID: 34424730
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Welishe F; Nakitende A; Akello L; Kunihira Tinka L; Nakimuli J; Ritar Kasidi J; Bishop O; Nakasendwa S; Baik Y; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PP; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2024 Feb; 21(2):e1004356. PubMed ID: 38377166
[TBL] [Abstract][Full Text] [Related]
10. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Swindells S; Ramchandani R; Gupta A; Benson CA; Leon-Cruz J; Mwelase N; Jean Juste MA; Lama JR; Valencia J; Omoz-Oarhe A; Supparatpinyo K; Masheto G; Mohapi L; da Silva Escada RO; Mawlana S; Banda P; Severe P; Hakim J; Kanyama C; Langat D; Moran L; Andersen J; Fletcher CV; Nuermberger E; Chaisson RE;
N Engl J Med; 2019 Mar; 380(11):1001-1011. PubMed ID: 30865794
[TBL] [Abstract][Full Text] [Related]
11. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
McIlleron H; Denti P; Cohn S; Mashabela F; Hoffmann JD; Shembe S; Msandiwa R; Wiesner L; Velaphi S; Lala SG; Chaisson RE; Martinson N; Dooley KE;
J Antimicrob Chemother; 2017 Jul; 72(7):2028-2034. PubMed ID: 28419277
[TBL] [Abstract][Full Text] [Related]
12. Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study.
Mapingure MP; Zech JM; Hirsch-Moverman Y; Msukwa M; Howard AA; Makoni T; Gwanzura C; Apollo T; Sandy C; Musuka GN; Rabkin M
J Int AIDS Soc; 2023 Jun; 26(6):e26105. PubMed ID: 37339341
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
[TBL] [Abstract][Full Text] [Related]
14. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
Park SW; Tasneen R; Converse PJ; Nuermberger EL
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
[TBL] [Abstract][Full Text] [Related]
15. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.
Moro RN; Scott NA; Vernon A; Tepper NK; Goldberg SV; Schwartzman K; Leung CC; Schluger NW; Belknap RW; Chaisson RE; Narita M; Machado ES; Lopez M; Sanchez J; Villarino ME; Sterling TR
Ann Am Thorac Soc; 2018 May; 15(5):570-580. PubMed ID: 29393655
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
Scriba TJ; Fiore-Gartland A; Penn-Nicholson A; Mulenga H; Kimbung Mbandi S; Borate B; Mendelsohn SC; Hadley K; Hikuam C; Kaskar M; Musvosvi M; Bilek N; Self S; Sumner T; White RG; Erasmus M; Jaxa L; Raphela R; Innes C; Brumskine W; Hiemstra A; Malherbe ST; Hassan-Moosa R; Tameris M; Walzl G; Naidoo K; Churchyard G; Hatherill M;
Lancet Infect Dis; 2021 Mar; 21(3):354-365. PubMed ID: 33508224
[TBL] [Abstract][Full Text] [Related]
17. Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.
Kendall EA; Hussain H; Kunkel A; Kubiak RW; Trajman A; Menzies R; Drain PK
BMC Med; 2021 Dec; 19(1):315. PubMed ID: 34903214
[TBL] [Abstract][Full Text] [Related]
18. Treatment of latent tuberculosis infection.
Parekh MJ; Schluger NW
Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
[TBL] [Abstract][Full Text] [Related]
19. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review.
Hamada Y; Ford N; Schenkel K; Getahun H
Int J Tuberc Lung Dis; 2018 Dec; 22(12):1422-1428. PubMed ID: 30606313
[TBL] [Abstract][Full Text] [Related]
20. [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial].
Geijo MP; Herranz CR; Vaño D; García AJ; García M; Dimas JF
Enferm Infecc Microbiol Clin; 2007 May; 25(5):300-4. PubMed ID: 17504682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
